US Capitol Capsule: Biopharma had 2013 legislative wins, despite 'Do-nothing' Congress
This article was originally published in Scrip
Executive Summary
While the House and the Senate got relatively little done in 2013 versus other years – with many in the US dubbing lawmakers this year a "do-nothing Congress" – 72 bills still managed to make it across the president's desk, with some of those pieces of legislation significantly affecting the biopharmaceutical industry.